TruAlt Bioenergy Reports Significant Profit Turnaround in Q1 FY26 Results
TruAlt Bioenergy reported strong Q1 FY26 unaudited results. Consolidated revenue grew to ₹30,389.17 lakh, and the company turned profitable with ₹472.52 lakh consolidated profit, a significant turnaround from last year's loss.
The announcement of unaudited financial results showing a turnaround from loss to profit and growth in revenue is a key performance indicator and will likely have a substantial influence on investor sentiment and the company's valuation.
The company reported a significant turnaround, moving from a consolidated loss of ₹2,151.37 lakh in Q1 FY25 to a consolidated profit of ₹472.52 lakh in Q1 FY26, alongside substantial revenue growth.
TruAlt Bioenergy Limited announced the publication of its unaudited financial results for the quarter ended June 30, 2025. The results were published in the Financial Express (English) and Vishwavani (Kannada) newspapers on October 21, 2025, including a Quick Response Code and webpage details for investor access. These results were approved by the Board of Directors in their meeting held on October 19, 2025, and are also available on the company's website.
Key financial highlights for the quarter ended June 30, 2025: * Consolidated Revenue from operations: ₹30,389.17 lakh, significantly up from ₹19,739.93 lakh in the quarter ended June 30, 2024. * Consolidated Profit before tax: ₹579.95 lakh, a substantial improvement from a loss of ₹2,159.08 lakh in the corresponding previous quarter. * Consolidated Profit for the period (after tax): ₹472.52 lakh, compared to a loss of ₹2,151.37 lakh in Q1 FY25. * Consolidated Basic Earnings Per Equity Share: ₹0.67. * Standalone Revenue from operations: ₹29,393.47 lakh, up from ₹19,140.14 lakh in Q1 FY25. * Standalone Profit before tax: ₹13.19 lakh, an improvement from a loss of ₹2,545.70 lakh in Q1 FY25. * Standalone Profit for the period (after tax): ₹2.77 lakh, compared to a loss of ₹2,509.39 lakh in Q1 FY25. * Standalone EBITDA: ₹3,489.18 lakh, with an EBITDA margin of 11.87%.
What to do with a filing like this
TruAlt Bioenergy Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by TruAlt Bioenergy Limited. Read the original for the full detail.